Lyrica (Pregabalin) Korean Post Marketing Surveillance Study

• Status: Completed
• Trial end date: 2011-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study collects post-marketing safety and efficacy surveillance data in real world clinical use of pregabalin for its approved indications in Korea.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Pregabalin

Criteria

Inclusion Criteria:

• Any patient treated with pregabalin for an approved indication by Korean Food and Drug Administration

Exclusion Criteria:

• Non-consenting

• Hypersensitivity to the active substance or to any of the excipients

• galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.